Clinical Trials Logo

Clinical Trial Summary

Spontaneous coronary artery dissection (SCAD) is a cause of acute coronary syndrome (ACS). Most patients are treated with beta-blockers (BB) and antiplatelet drugs (AP) on empiric basis. The Beta-Blockers and Antiplatelet Agents in Patients with Spontaneous Coronary Artery Dissection (BA-SCAD) randomized clinical trial is an academic, pragmatic, nation-wide, prospective study developed under the auspices of the Spanish Society of Cardiology (SEC) that aims to assess the efficacy of medical therapy in SCAD patients. Using a factorial 2x2 design, patients will be randomized (1:1/1:1) to: 1) BB (yes/no) and 2) short AP regimen (1 month) vs prolonged dual AP therapy (DAPT) (12 months).Only patients with preserved left ventricular ejection fraction (LVEF) will be randomized to BB (yes/no) because patients with LVEF <40% will receive BB according to current guidelines. Likewise, only medically managed patients will be randomized to short AP therapy vs 1-year DAPT. The study will have a pragmatic, open label, blind outcomes design (PROBE). A total of 600 SCAD patients will be randomized within 2 years (300 per arm in a factorial 2x2 design). The primary efficacy endpoint will include the composite of death, acute myocardial infarction (MI), stroke, coronary revascularization, recurrent SCAD, and unplanned hospitalization for ACS or heart failure at 1 year. The primary safety endpoint will be bleeding. All patients will be clinically followed yearly. The main study will be pragmatic but a comprehensive set of additional studies (clinical, imaging, biomarkers, inflammatory, immunologic, pharmacogenetic and genetic) will be organized to ensure an holistic view on this challenging condition.


Clinical Trial Description

Spontaneous coronary artery dissection (SCAD) is a relatively rare but important and increasingly recognized cause of acute coronary syndrome (ACS). Most patients presenting with SCAD are treated with beta-blockers (BB) and antiplatelet drugs (AP). Although appealing from a pathophysiological standpoint, such management strategy is completely empiric. The Beta-Blockers and Antiplatelet Agents in Patients with Spontaneous Coronary Artery Dissection (BA-SCAD) randomized clinical trial is an academic, pragmatic, nation-wide, prospective study developed under the auspices of the Spanish Society of Cardiology (SEC) that aims to assess the efficacy of medical therapy in SCAD patients. Using a factorial 2x2 design, patients will be randomized (1:1/1:1) to: 1) BB (yes/no) and 2) short AP regimen (1 month) vs prolonged dual AP therapy (DAPT) (12 months). A conservative medical management will be initially recommended, with coronary revascularization reserved for patients with ongoing/refractory ischemia. Only patients with preserved left ventricular ejection fraction (LVEF) will be randomized to BB (yes/no) because patients with LVEF <40% will receive BB according to current guidelines. Likewise, only medically managed patients will be randomized to short AP therapy vs 1-year DAPT, because patients requiring coronary interventions will receive DAPT. The study will have a pragmatic, open label, blind outcomes design (PROBE). The type and dose of BB and AP agents will be at the discretion of the treating physician. Treatment adherence will be reinforced and closely monitored and the potential influence of drug discontinuation/cross-over on outcomes will be carefully evaluated. A total of 600 SCAD patients will be randomized within 2 years (300 per arm in a factorial 2x2 design). The primary efficacy endpoint will include the composite of death, acute myocardial infarction (MI), stroke, coronary revascularization, recurrent SCAD, and unplanned hospital admission for ACS or heart failure at 1 year. The primary safety endpoint will be bleeding according the Bleeding Academic Research Consortium (BARC) criteria ≥ 3. An analysis of net clinical benefit, including primary efficacy and safety endpoints, will also be performed. All patients will be clinically followed at 1 year (primary endpoint) and yearly thereafter. Although the main study will be pragmatic, following routine clinical practice, a systematic and comprehensive set of additional ancillary studies and investigations (clinical, imaging, biomarkers, inflammatory, immunologic, pharmacogenetic and genetic) will be prospectively organized to ensure a multidisciplinary and holistic view on this challenging condition. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04850417
Study type Interventional
Source Spanish Society of Cardiology
Contact Fernando Alfonso, MD
Phone 34 680483165
Email falf@hotmail.com
Status Not yet recruiting
Phase Phase 4
Start date April 30, 2021
Completion date December 31, 2028

See also
  Status Clinical Trial Phase
Recruiting NCT01967511 - Defining the Basis of Fibromuscular Dysplasia (FMD)
Enrolling by invitation NCT03876847 - Genetics of Spontaneous Coronary Artery Dissection (SCAD-INSPIRE Genetics)
Completed NCT03390998 - Angiographic and Psychosocial Evaluation of Peripartum vs. Non: SCAD
Completed NCT02799186 - The Study of the Prevalence Fibromuscular Dysplasia in Patient With Haematoma or Spontaneous Coronary Artery Dissection. N/A
Enrolling by invitation NCT01427179 - Genetic Investigations in Spontaneous Coronary Artery Dissection (SCAD)
Recruiting NCT04496687 - International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry
Active, not recruiting NCT02188069 - Canadian SCAD Study
Recruiting NCT06323811 - Comparison of Free-breathing 3D Quantitative Perfusion in Patients With MINOCA and MINOCA-mimics N/A
Recruiting NCT05699200 - A Study to Analyze the Role of Sympathetic Nervous System in Spontaneous Coronary Artery Dissection N/A
Recruiting NCT01429727 - The "Virtual" Multicenter Spontaneous Coronary Artery Dissection (SCAD) Registry
Recruiting NCT03607981 - Spanish Registry on Spontaneous Coronary Artery Dissection
Completed NCT04415762 - Spontaneous Coronary Artery Dissection Registry (DIssezioni Spontanee COronariche ITalian-SPAnish)
Recruiting NCT04906356 - Canadian SCAD Study
Recruiting NCT04457544 - Spontaneous Coronary Artery Dissection National Swiss Registry
Withdrawn NCT03335020 - Using Ultrasonography, Shear Wave Elastography, Strain Imaging, and 3-D Volume Ultrasonography on Cardiovascular Disease Phase 1